en · de · es · fr · pt
semax-notes.peptides6088.com › Blog › Background And Development — 2026 Update

Background And Development — 2026 Update

By Editorial Desk · published 2026-06-20 · last reviewed 2026-08-01 · Blog

Everything below concerns neurotrophic factor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Mechanisms and Research Directions

Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.

Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Structure and Research Background

Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Related pages on this site

Storage Handling and Analytical Verification

Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.

Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.

Semax Peptide Background and Identity

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax 的储存、稳定性与分析

溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集,其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸,因此氧化风险相对突出。工作液一般主张现配现用,或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率,而关于最佳条件的公开数据并不统一。

常规纯度与身份确认依赖反相高效液相色谱,并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成,肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同,因此各实验室报告的纯度数值不宜直接横向比较。

多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下,同时避免光照与反复升温。短期运输有时采用冷藏条件,但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数,以降低吸湿和微生物污染的风险。开封后若未一次用完,建议在干燥环境中密封并尽快放回低温储存。

Further detail

=== Tyrosine residues in resilin === Andersen, in 1996, discovered that the tyrosine residues are involved in chemically covalent cross-links in many forms such as dityrosine, trityrosine, and tetratyrosine. Primarily, in resilin, tyrosine and dityrosine served as the chemical cross-links, in which R groups of Tyrosine and Dityrosine add to the backbone of the growing peptide chain. Andersen came to this conclusion based on a study involving these two compounds in which he was able to rule out other forms of cross linking such as disulfide bridges, ester groups, and amide bonds. Though the mechanism of cross-linking of Tyrosine is understood that occurs through radical initiation, the cross linking of resilin still remains a mystery. Cross linking of resilin occurs very quickly and this is possibly a result of temperature. At increasing temperature, the rate of cross linking of the residues increases and leads to a highly cross-linked resilin network. The amino acid composition of resilin indicates that proline and glycine has a relatively high presence in the amino acid composition of resilin. The presence of glycine and proline in the composition of resilin contributes greatly to the elasticity of resilin. Resilin, however, has an absence of an alpha-helix leading to a randomly coiled structure and a disordered structure. This is primarily due to the significantly high proline content in resilin. Proline is a bulky amino acid that has the ability to cause a kink the peptide chain and due to the sterically hindered side chains, it is not able to fit in the alpha-helices.

== Epidemiology == Coronary artery disease is the leading cause of death in men and women. This condition is the cause of one third of all deaths, which is especially worse in areas with lower socioeconomic status. Mortality is nearly five times higher in men than women, but mortality difference narrows with age. Black women are more likely than white women to have a heart attack. Black adults have a higher mortality rate than white adults from heart attack. Asian adults have the least incidence of coronary artery disease. Asian Indian men, Filipino men and Filipino women have a higher risk than white people. Young Hispanic women who have a heart attack have a higher mortality rate than young Hispanic men. They have a higher mortality rate than young Black adults and young white adults.

== Function == The broad distribution of relaxin-3 fibres/RXFP3 within several key neuronal circuits suggests an ability to modulate a broad range of behaviours. This has been confirmed in a growing number of rodent studies, which demonstrate relaxin-3 is able to modulate arousal, the response to stress, feeding/metabolism and memory; and likely plays a role in the generation/regulation of hippocampal theta rhythm.

Sources: en.wikipedia.org

Supporting material

==== MeSH E05.318.308 – data collection ==== MeSH E05.318.308.225 – geriatric assessment MeSH E05.318.308.250 – health surveys MeSH E05.318.308.250.149 – behavioral risk factor surveillance system MeSH E05.318.308.250.300 – dental health surveys MeSH E05.318.308.250.300.300 – dental plaque index MeSH E05.318.308.250.300.350 – dmf index MeSH E05.318.308.250.300.675 – oral hygiene index MeSH E05.318.308.250.300.725 – periodontal index MeSH E05.318.308.250.475 – health status indicators MeSH E05.318.308.250.475.365 – apache MeSH E05.318.308.250.475.547 – severity of illness index MeSH E05.318.308.250.475.547.500 – karnofsky performance status MeSH E05.318.308.250.475.730 – sickness impact profile MeSH E05.318.308.250.580 – mass screening MeSH E05.318.308.250.580.174 – anonymous testing MeSH E05.318.308.250.580.350 – genetic screening MeSH E05.318.308.250.580.510 – mass chest x-ray MeSH E05.318.308.250.580.560 – multiphasic screening MeSH E05.318.308.250.580.580 – neonatal screening MeSH E05.318.308.250.580.925 – vision screening MeSH E05.318.308.250.600 – nutrition surveys MeSH E05.318.308.250.600.350 – diet surveys MeSH E05.318.308.250.700 – population surveillance MeSH E05.318.308.250.700.650 – sentinel surveillance MeSH E05.318.308.335 – health care surveys MeSH E05.318.308.420 – interviews MeSH E05.318.308.420.200 – focus groups MeSH E05.318.308.502 – narration MeSH E05.318.308.585 – nutrition assessment MeSH E05.318.308.585.550 – nutrition surveys MeSH E05.318.308.585.550.350 – diet surveys MeSH E05.318.308.750 – questionnaires MeSH E05.318.308.940 – records MeSH E05.318.308.940.250 – birth certificates MeSH E05.318.308.940.350 – death certificates MeSH E05.318.308.940.375 – dental records MeSH E05.318.308.940.425 – hospital records MeSH E05.318.308.940.968 – medical records MeSH E05.318.308.940.968.500 – medical record linkage MeSH E05.318.308.940.968.625 – medical records systems, computerized MeSH E05.318.308.940.968.750 – medical records, problem-oriented MeSH E05.318.308.940.968.875 – trauma severity indices MeSH E05.318.308.940.968.875.125 – abbreviated injury scale MeSH E05.318.308.940.968.875.250 – glasgow coma scale MeSH E05.318.308.940.968.875.260 – glasgow outcome scale MeSH E05.318.308.940.968.875.500 – injury severity score MeSH E05.318.308.940.984 – nursing records MeSH E05.318.308.970 – registries MeSH E05.318.308.970.725 – seer program MeSH E05.318.308.985 – vital statistics MeSH E05.318.308.985.450 – life expectancy MeSH E05.318.308.985.475 – life tables MeSH E05.318.308.985.525 – morbidity MeSH E05.318.308.985.525.080 – basic reproduction number MeSH E05.318.308.985.525.375 – incidence MeSH E05.318.308.985.525.750 – prevalence MeSH E05.318.308.985.550 – mortality MeSH E05.318.308.985.550.250 – cause of death MeSH E05.318.308.985.550.287 – child mortality MeSH E05.318.308.985.550.325 – fatal outcome MeSH E05.318.308.985.550.362 – fetal mortality MeSH E05.318.308.985.550.400 – hospital mortality MeSH E05.318.308.985.550.475 – infant mortality MeSH E05.318.308.985.550.500 – maternal mortality MeSH E05.318.308.985.550.900 – survival rate MeSH E05.318.308.985.775 – pregnancy rate MeSH E05.318.308.985.775.500 – birth rate

Vancomycin biosynthesis occurs primarily via three nonribosomal protein syntheses (NRPSs) VpsA, VpsB, and VpsC. The enzymes determine the amino acid sequence during its assembly through its 7 modules. Before vancomycin is assembled through NRPS, the non-proteinogenic amino acids are first synthesized. L-tyrosine is modified to become the β-hydroxytyrosine (β-HT) and 4-hydroxyphenylglycine (4-Hpg) residues. 3,5-dihydroxyphenylglycine ring (3,5-DPG) is derived from acetate.

Peptides are short chains of amino acids linked by peptide bonds. A polypeptide is a longer, continuous, unbranched peptide chain. Polypeptides that have a molecular mass of 10,000 Da or more are called proteins. Chains of fewer than twenty amino acids are called oligopeptides, and include dipeptides, tripeptides, and tetrapeptides. Amino acids comprise peptides as residues. Peptides are usually linear polymers with a free amine at one end (the so-called N-terminus) and a carboxyl group at the other (the C-terminus). Macrocyclic peptides are a distinct class.

Sources: en.wikipedia.org

Notes from published material

Since then the exclusive approach to Bolivia has been accentuated more and more in his life as an outlaw, and from the depth of his disappointment he has to look at Peru as an enemy country." Despite the defeat of the Peruvian-Bolivian Confederation (where Santa Cruz and other foreign politicians proposed to Chile plans to divide Peru as a sudden measure, without success), Santa Cruz, Orbegoso and many other of their supporters (after being defeated in 1839) took refuge in Ecuador, who planned to organize expeditions to northern Peru, to undermine the Gamarra regime. Santa Cruz, who still held out hope of regaining power in Bolivia (where he still had supporters), continued to plot against Peru from Ecuador (contributing to increase the anti-Peruvian sentiment in that country). Although it was unlikely that he would succeed in reconstituting the Confederation, Santa Cruz had a minimal plan: to annex southern Peru to Bolivia (and, if possible, weaken the northern Peruvian state in the face of an Ecuadorian territorial preponderance). From various letters preserved, it is known that his major plan was to promote an alliance between Ecuador and New Granada to attack Peru. It is therefore not by chance that at that time, Ecuador began its territorial demands towards Peru, claiming Tumbes, Jaén and Maynas. There is no doubt that those who incited Ecuador to make this claim were Santa Cruz and other enemies of the Peruvian government taking refuge in its territory.

Human feces (American English) or faeces (British English), commonly and in medical literature more often called stool, commonly referred to as poo or poop, are the solid or semisolid remains of food that could not be digested or absorbed in the small intestine of humans, but has been further broken down by bacteria in the large intestine. It also contains bacteria and a relatively small amount of metabolic waste products such as bacterially altered bilirubin, and the dead epithelial cells from the lining of the gut. It is discharged through the anus during a process called defecation. Human feces have similarities to the feces of other animals and varies significantly in appearance (i.e. size, color, texture), according to the state of the diet, digestive system, and general health. Normally, human feces are semisolid, with a mucus coating. Small pieces of harder, less moist feces can sometimes be seen impacted in the distal (final or lower) end. This is a normal occurrence when a prior bowel movement is incomplete, and feces are returned from the rectum to the large intestine, where water is further absorbed. Human feces together with human urine are collectively called human waste or excretion. Containing human feces and preventing spread of pathogens from human feces by the fecal–oral route are the main goals of sanitation.

== Treatment == Treatment depends on the type of amyloidosis that is present. Treatment with high dose melphalan, a chemotherapy agent, followed by stem cell transplantation has shown promise in early studies and is recommended for stage I and II AL amyloidosis. However, only 20–25% of people are eligible for stem cell transplant. Chemotherapy treatment including cyclophosphamide-bortezomib-dexamethasone-daratumumab (Dara-Cybord) is currently the recommended treatment option for people with AL Amyloidosis not eligible for transplant. In AA, symptoms may improve if the underlying condition is treated. In people who have inflammation caused by AA amyloidosis, tumour necrosis factor (TNF)-alpha inhibitors such as infliximab and etanercept are used for an average duration of 20 months. If TNF-alpha inhibitors are not effective, Interleukin-1 inhibitors (e.g., anakinra, canakinumab, rilonacept) and interleukin-6 inhibitors (e.g., tocilizumab) may be considered. Management of ATTR amyloidosis will depend on its classification as wild type or variant. Both may be treated with tafamidis, a low toxicity oral agent that prevents destabilization of correctly folded protein. Studies showed tafamidis reduced mortality and hospitalization due to heart failure. Previously, for variant ATTR amyloidosis, liver transplant was the only effective treatment. New therapies include diflunisal, inotersen, and patisiran. Diflunisal binds to misfolded mutant TTR protein to prevent its buildup, like how tafamidis works.

== Cellular functions == Proteins are the chief actors within the cell, said to be carrying out the duties specified by the information encoded in genes. With the exception of certain types of RNA, most other biological molecules are relatively inert elements upon which proteins act. Proteins make up half the dry weight of an Escherichia coli cell, whereas other macromolecules such as DNA and RNA make up only 3% and 20%, respectively. The set of proteins expressed in a particular cell or cell type is known as its proteome.

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

What is the leading proposed mechanism?

The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.

Network